

REMARKS/ARGUMENTS

By the present amendment, applicants have canceled Claims 7-9 and 15-21. In addition, applicants have amended the claims to place the claims in better form and remove multiple dependencies. No new matter has been added. Therefore, the claims remaining for consideration by the Examiner are Claims 1-6, 10-14, and 22-33.

The foregoing amendments to the specification are to place the Abstract on a separate sheet. Should the Examiner have any questions, please contact the undersigned attorney.

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7945


John D. Thallemer
Attorney for Applicants
Reg. No. 34,940

Date: October 10, 2005